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Abstract
Background: Building up of pathway-/disease-relevant signatures provides a persuasive tool for understanding the
functional relevance of gene alterations and gene network associations in multifactorial human diseases. Ovarian
cancer is a highly complex heterogeneous malignancy in respect of tumor anatomy, tumor microenvironment
including pro-/antitumor immunity and inflammation; still, it is generally treated as single disease. Thus, further
approaches to investigate novel aspects of ovarian cancer pathogenesis aiming to provide a personalized strategy
to clinical decision making are of high priority. Herein we assessed the contribution of the AID/APOBEC family and
their associated genes given the remarkable ability of AID and APOBECs to edit DNA/RNA, and as such, providing
tools for genetic and epigenetic alterations potentially leading to reprogramming of tumor cells, stroma and
immune cells.
Results: We structured the study by three consecutive analytical modules, which include the multigene-based
expression profiling in a cohort of patients with primary serous ovarian cancer using a self-created AID/APOBEC-
associated gene signature, building up of multivariable survival models with high predictive accuracy and
nomination of top-ranked candidate/target genes according to their prognostic impact, and systems biology-
based reconstruction of the AID/APOBEC-driven disease-relevant mechanisms using transcriptomics data from
ovarian cancer samples. We demonstrated that inclusion of the AID/APOBEC signature-based variables significantly
improves the clinicopathological variables-based survival prognostication allowing significant patient stratification.
Furthermore, several of the profiling-derived variables such as ID3, PTPRC/CD45, AID, APOBEC3G, and ID2 exceed the
prognostic impact of some clinicopathological variables. We next extended the signature-/modeling-based knowledge
by extracting top genes co-regulated with target molecules in ovarian cancer tissues and dissected potential networks/
pathways/regulators contributing to pathomechanisms. We thereby revealed that the AID/APOBEC-related network in
ovarian cancer is particularly associated with remodeling/fibrotic pathways, altered immune response, and autoimmune
disorders with inflammatory background.
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Conclusions: The herein study is, to our knowledge, the first one linking expression of entire AID/APOBECs and
interacting genes with clinical outcome with respect to survival of cancer patients. Overall, data propose a novel AID/
APOBEC-derived survival model for patient risk assessment and reconstitute mapping to molecular pathways. The
established study algorithm can be applied further for any biologically relevant signature and any type of diseased
tissue.
Keywords: The AID/APOBEC family, Multigene signature, Primary serous ovarian carcinoma, Multivariable survival
models, Prognostic effect, Integrated analysis of disease-relevant pathways
Background
Accumulated knowledge on dysregulated cellular
checkpoints associated with cancer development and
systematic studies using genomic analysis tools have
suggested many new classes of cancer-causing and/or
cancer-promoting genes. The discovery of AID/APO-
BEC gene family members with their potential multifa-
ceted contribution to malignant transformation gave a
fundamental impact [1, 2]. In humans, the AID/APO-
BEC family consists of eleven molecules including AID
(activation-induced cytidine deaminase, gene name:
AICDA) and APOBECs (apolipoprotein B mRNA edit-
ing enzyme, catalytic polypeptide-like) with the remark-
able ability to edit DNA or RNA through cytosine
deamination and thus providing tools to introduce
DNA or RNA alterations/damages [3–5]. Under physio-
logical conditions, AID is expressed in activated B cells
within germinal centers and responsible for the diversi-
fication processes of the immunoglobulin genes by trig-
gering both somatic hypermutation and class switch
recombination events [6]. Beside genetic modifications
it has been shown that AID may also contribute to epi-
genetic reprogramming by deaminating methylated
cytosine [7]; in conjunction with T:G mismatch repair,
this leads to DNA demethylation. The APOBEC3 sub-
family (containing seven members) has been implicated
in the innate immune defense against endogenous
transposable genetic elements, endogenous retroviruses
as well as exogenous viruses [8–10] based on the ability
to induce DNA damage. In contrast to other family
members, APOBEC1 was characterized as RNA-editing
enzyme by targeting the ApoB pre-mRNA [1, 11]; later
additional mRNA targets have been described [12].
Given that under pathological circumstances AID and
APOBECs’ aberrant expression/activity and/or aberrant
mechanisms of recruitment to target(s) and/or aberrant
processing of the resulting mismatches might take
place, their oncogenicity and contribution to the devel-
opment and/or progression of cancer have been pro-
posed [2, 13–23]. In B-cell malignancies, AID is
responsible for DNA damage leading to double-strand
DNA breaks followed by translocation of oncogenes
[24–28]. In respect of solid tumors, the importance of
AID for oncogenesis was strengthened since it became evi-
dent that under pathophysiological circumstances including
chronic inflammation the AID expression and activity is
not restricted to B cells and Ig locus; AID can also mutate
non-Ig genes including among others TP53 and the
CDKN2b-CDKN2a locus as targets [20, 28–32]. Among
the organs of cancerous or inflamed tissues in which
ectopic expression of AID was thus far detected in cells of
non-B-cell origin are liver, esophagus, lung, stomach, and
colon [20, 29, 31, 33–35]. Beside AID, APOBEC2 was
recently identified as risk factor in liver and lung tumori-
genesis [19]. Importantly, two independent meta-analyses-
based studies identified a link between deleterious somatic
mutations with cytosine mutation bias in several cancer
types and APOBEC expression/enzymatic activities, with
one member of the APOBEC3 subfamily, APOBEC3B,
being responsible for the majority of cytosine mutations
[13, 36]. It was proposed that for breast cancer APOBEC3B
may represent a new marker and target [13, 37].
Here we tested the hypothesis that AID and/or other
members of the AID/APOBEC family could be part of
mechanism(s) contributing to the pathophysiology of
ovarian cancer. The rationale behind is enhanced by
additional puzzling evidence. Ovarian cancer shows a
high degree of genomic instability; practically all classes
of mutations, including point mutations and large
genomic deletions and insertions, were demonstrated
in high-grade serous ovarian cancer in several genes in-
cluding BRCA1/2 and mutational inactivation of TP53
[38]. AID mRNA expression was shown to be induced
by estrogen in an ovarian cancer cell line in vitro [39].
A recent study showed that APOBEC3B overexpression
in ovarian cancer correlated with elevated levels of
transversion mutations [40]; however, the clinical rele-
vance of these findings still needs to be demonstrated
including the potential prognostic relevance. Generally,
the overview picture covering the mutual interrelation
of all family members and their association with the
clinical outcome of ovarian cancer patients is not yet
available. Further aspect to consider is that the ovarian
cancer cells may express several AID/APOBEC family
members acting in a patient-specific manner; yet, the
tumor-infiltrating immune cells of various subsets may
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as well express more than one molecule, each contrib-
uting to diverse, not-yet-known pathomechanisms.
Thus, the systems-level overview is required. Although
ovarian cancer is a heterogeneous malignancy, it is
generally treated as a single disease with the use of
standard chemotherapy with platinum derivatives and
taxanes after surgery. The treatment strategies might
undergo a substantial transformation based on the
promising novel treatment options under clinical trials
[41]. While high response rates to the initial regimen
are observed, a relapse is seen in most of the patients
due to the rapid development of drug resistance con-
tributing to the overall poor survival characterized by a
5 year overall survival rate of < 40 % [42, 43]. Therefore,
algorithms to investigate novel aspects of ovarian can-
cer pathophysiology aiming to identify novel molecules/
pathways suitable to be used as prognostic or predictive
biomarkers and/or drug targets and, thus, to provide a
personalized approach to clinical decision making are
of high priority.
We and others recently showed (examples in [44–47])
that building up of pathway-/disease-relevant signatures
provides a persuasive tool for understanding the func-
tional relevance of gene alterations and gene network as-
sociations in human diseases and might be taken as
basis for prognostic models assessing patient risk/sur-
vival. Evidently, interpretation of a single gene expres-
sion pattern under diseased conditions might not be
sufficient to understand its role in disease pathogenesis;
yet, particular genes composing a multigene signature
might be reciprocally interconnected within canonical or
not-yet-defined disease-relevant pathway(s). We herein
aimed to build up a multigene-based model that is eli-
gible as prognostic for patients with advanced stage of
serous ovarian carcinoma and to define novel key AID/
APOBEC-associated aspects of ovarian cancer. A compre-
hensive analysis was applied linking multigene signature-
based expression profiling of ovarian cancer specimens
with statistical modeling followed by systems biology-
based data mining and analysis of disease-relevant
biological mechanisms. An overview of the analysis steps
is outlined in Fig. 1.
Methods
Profile of study patients
Tumor samples of epithelial ovarian cancer (EOC) were
collected in the course of the European Commission’s
sixth framework program project OVCAD from five
European university hospitals (Ovarian Cancer: Diagno-
sis of a silent killer; grant agreement no. 018698) [48].
Information on clinicopathological characteristics was
documented by experienced clinicians. The clinicopatho-
logical characteristics of the 186 patients with primary
EOC are summarized in Table 1; the patient group is a
part of the patient cohort under study of the OVCAD
consortium [49, 50]. Patient inclusion criterion com-
prises the epithelial ovarian cancer with advanced dis-
ease (FIGO II – IV); the majority of patients had
advanced-stage ovarian cancer (FIGO III and IV, 95 %),
G3 tumors (74 %), and the majority of tumors was of
serous histology (88 %). 71 % of patients could be opti-
mally cytoreduced with no residual disease after initial
surgery; absence of residual disease was defined as
macroscopically complete resection of tumor material.
All patients received standard adjuvant chemotherapy
including platinum-based anti-cancer agents. Eight per-
cent of patients received neoadjuvant chemotherapy.
Patients with recurrence or progressive disease until
6 months after the end of chemotherapy were defined as
chemotherapy resistant. The median age at diagnosis
was 57 years (range, 26 to 85 years); the median follow-
up time was 30.0 months (95 % CI: 27.4-32.6). There
were 54 cases (29 %) of death related to EOC reported
during the follow-up period, designated as events below.
Cell lines
The human ovarian carcinoma cell lines A2780 and
A2780ADR were obtained from the European Collec-
tion of Cell Cultures (Salisbury, Wiltshire, United
Kingdom). A2780 is the parent line to the adriamycin
resistant A2780ADR. Although adriamycin is not a
therapy regimen for ovarian cancer, but considering
that A2780 cell model is featured by high chemosensi-
tivity to cisplatin, while A2780ADR cell line exhibits a
collateral resistance to cisplatin, both cell lines are
often used as in vitro models to study the acquisition
of drug resistance [51, 52]. The human ovarian carcin-
oma cell lines OVCAR-3 and SK-OV-3 were obtained
from the ATCC (Manassas, VA). The cell lines were
maintained in phenol-red-free RPMI-1640 medium
supplemented with L-glutamine (PAN-Biotech GmbH,
Aidenbach, Germany), 10 % Foetal Calf Serum (FCS)
(Invitrogen, Carlsbad, CA) and 1 % penicillin (10,000
U/ml)/streptomycin (10 mg/ml) solution (Invitrogen) in
a humidified atmosphere at 37 °C with 5 % CO2.
RNA isolation from tumor tissues and ovarian cancer cell
lines
Total RNA from tissues was isolated using the ABI 1600
nucleic acid prepstation (Applied Biosystems, Foster
City, CA, USA) following the instructions of the manu-
facturer as described previously [49]. Total RNA from
A2780, A2780ADR, OVCAR-3 and SK-OV-3 cell lines
was isolated using the RNeasy Mini kit (Qiagen, Hilden,
Germany) including DNase I treatment. The concentra-
tion, purity and integrity of RNA samples were determined
on a Nanodrop ND-1000 (Kisker-Biotech, Steinfurt,
Germany) and agarose gel electrophoresis.
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Real-time PCR analysis
0.5 μg of total RNA from tissue specimens and 1 μg of
total RNA from the cell lines was reverse transcribed
using the High Capacity cDNA RT kit (Applied Biosys-
tems) according to the instructions of the manufacturer.
Given the patient-specific composition of various cell
types within ovarian cancer tissues, for accurate
normalization of mRNA between ovarian cancer tissue
specimens we selected ACTB, TOP1, UBC, and YWHAZ
out of a panel of 12 housekeeping genes (HKGs) as
appropriate reference genes using a geNorm kit (Primer-
Design Ltd., Southampton, UK) and the geNorm soft-
ware [53]. For the cancer cell lines, EEF1A1 and UBC
were used as appropriate reference HKGs as estimated
Fig. 1 Overview of the study design: from gene expression profiling-based data sets to prognostic models for clinical outcome and biologically
meaningful, disease-associated pathways. The proposed algorithm includes three major blocks. (1) The composition of the AID/APOBEC-associated
multigene signature (n = 24) is assembled based on a knowledge-driven approach and applied for the real-time PCR-based gene expression
profiling of a clinically well-characterized patient cohort with primary ovarian carcinoma (n = 186). (2) Twenty one profiling-derived variables are
correlated with survival data. Univariate Cox regression analysis is applied to assess the prognostic effect of each individual gene and clinical
variable. Multivariable Cox regression analysis is applied to build up the survival prognostic models accounting for mutual interconnections
between the genes from the signature. Two different multivariable modeling algorithms are used. As outcome, three types of models are created:
(i) Clinics – the model is based on the clinicopathological parameters only; (ii) AID/APOBEC – the model is based on the multigene profiling-
derived data sets; and (iii) Combined – the model is based on the clinicopathological and gene profiling-derived variables in combination. In both
algorithms the standardized coefficients (STDBETA) are used for ranking the individual variables in a model by their importance. The top-ranked
genes are defined as target genes for the follow-up analyses. Important to note, parameters such as proportion of explained variation (PEV),
c-index and p-value are calculated and used to compare the predictive accuracy and discriminative ability of the individual models. Alignment
with patients’ survival data is illustrated by Kaplan-Meier estimates showing patient stratification into low, intermediate, and high risk groups. (3)
Systems biology approach is used to assign the defined target genes with prognostic impact to disease-relevant biological pathways. Firstly, the
web-based analysis platform for publically available microarray datasets (GENEVESTIGATOR) is used to extract the top genes co-regulated with the
target genes in ovarian cancer tissues based on inclusion criteria specified in Methods. Secondly, the obtained gene lists are subjected to the
Ingenuity-based core analysis. As input, in addition to the individual lists of co-regulated genes, the combined list (“mixed”) is used to mimic the
mutual interconnections within the multigene signature. The core analysis includes alignment with Canonical Pathways, Functional Annotations &
Diseases and Upstream Regulators. Thirdly, Spotfire, a data discovery and visualization software, is used for large-scale IPA-derived data processing
and data mining. As final outcome, the 10-top Pathways/Functions/Regulators are defined
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by DataAssist software (Applied Biosystems). Primers for
genes of interest composing the AID/APOBEC-associ-
ated multigene signature were designed using Primer
Express 3.0 software (Applied Biosystems) and validated
using a normal tissue panel (Takara, Clontech Laborator-
ies Inc., Mountain View, USA) as previously described
[45]. Primer sequences are displayed in Additional file 1:
Table S1. The assay for ACTB was from Applied Biosys-
tems; assays for the reference HKGs TOP1, UBC, and
YWHAZ were purchased from PrimerDesign Ltd; primers
for ESR1 and ESR2 were purchased from Applied Biosys-
tems (Additional file 1: Table S2).
Real-time PCR analysis was performed on ABI 7900HT
instrument equipped with SDS 2.3 software (Applied Bio-
systems) in the 384-well plate format using POWER SYBR
Green Master Mix (Applied Biosystems) or, in case
hydrolysis probe assays were used, Gene Expression Mas-
ter Mix (Applied Biosystems). The qPCR Human Refer-
ence Total RNA (Clontech Laboratories Inc.) was assigned
as calibrator sample to which gene expression levels of all
other samples are compared. Subsequently, raw Ct values
were exported into Microsoft Excel and results were cal-
culated using the ΔΔCt method [54] as relative quantities
(RQ) normalized to the geometric mean of the four or of
the two HKGs specified above for ovarian cancer tissues
and cells lines, respectively, and shown relative to the cali-
brator sample.
The composition of the AID/APOBEC-associated mul-
tigene signature used for profiling of the patient cohort
and the cell lines is specified in Results.
Statistical analysis
Profiling-derived values were log2 transformed for Cox
regression models to avoid disproportional impact of
outliers. Missing values were imputed using the R pack-
age mice [55]. Correlation coefficients were calculated
by Pearson's correlation for log2 transformed values
using SPSS. Hazard ratios and corresponding 95 % con-
fidence intervals were estimated by univariate Cox re-
gression analysis for both the clinicopathological
variables and the gene profiling-based variables using
the IBM SPSS statistical package (version 20.0; SPSS
Inc., an IBM company, Chicago, USA). Regularized mul-
tivariable Cox regression was applied to develop prog-
nostic models using two types of regularization as
specified below. Calculations were performed with the R
(R Foundation for Statistical Computing, Vienna,
Austria) package glmnet [56]. In the first approach, Cox
regression with a ridge penalty (ridge) was used for esti-
mating multivariable models. In the second approach,
models were generated by simultaneous parameter
shrinkage and variable selection using the LASSO (L1-
norm penalization). Both approaches introduce a penalty
to the likelihood function in order to reduce the infla-
tion of variance of the predictions (overfit) caused by a
critical ratio of number of outcome events and number
of variables. While by the ridge penalty all variables will
enter the final model but with severely shrunken regres-
sion coefficients, the LASSO penalty selects only some
of the variables for the final model, and assigns regres-
sion coefficients of 0 to all other variables. The tuning
parameter lambda of the ridge and the LASSO penalties
were optimized by minimizing the Cox model’s partial
deviance in a leave-one-out cross-validation procedure.
An additional leave-one-out cross-validation loop was
wrapped around the model development process to ob-
tain cross-validated predictors for each patient. Here,
the model was re-estimated N times each time omitting
one patient in turn, and the cross-validated predictor for
that patient was computed as the vector product of the
Table 1 Clinicopathological characteristics of study patients
Patients (%) 186 (100.0)
Age at diagnosis [years]
Median (range) 57 (26–85)
Progression-free survival [months]
Median (range) 16 (1–48)
Number of recurrencies (%) 106 (57.0)
Overall survival [months]
Median (range) 24 (1–49)
Number of deaths (%) 54 (29.0)
Histology (%)
Serous 164 (88.2)
Non-serous 22 (11.8)
FIGO (%)
II 9 (4.8)
III 148 (79.6)
IV 29 (15.6)
Grading (%)
1 6 (3.2)
2 43 (23.1)
3 137 (73.7)
Residual disease after initial surgery (%)
None 132 (71.0)
≤ 1 cm 34 (18.3)
> 1 cm 20 (10.8)
Type of chemotherapy (%, 30 missing [16.1 %])
Adjuvant 124 (66.7)
Neoadjuvant 15 (8.1)
Intraperitoneal 17 (9.1)
Response to first-line chemotherapy (%, 1 missing)
Responder 138 (74.2)
Non-Responder 47 (25.3)
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re-estimated regression coefficients and the patient’s cor-
responding gene expression values. Global p-values for
each model were calculated in SPSS using univariate
Cox proportional hazards analysis with the corresponding
cross-validated predictors of the model as single covariate.
Overall survival (OS) and progression-free survival (PFS)
were shown by Kaplan-Meier graphs, stratified by quantiles
of the cross-validated linear predictors, and accompanied
by corresponding log-rank test p-values. Using the cross-
validated predictors, we also assessed the discriminative
ability of the model by determining the concordance index
(c-index) [57] and its proportion of explained variation
(PEV) [58]. The c-index is a discrimination measure and
describes, as an average measure over all possible pairs of
patients, the concordance of survival times and linear pre-
dictors derived from the model. The measure is adjusted
by inverse probability weighting techniques to accommo-
date censored survival times. PEV describes the relative
gains in predictive accuracy of the survival status at any
time point during follow-up when prediction based on co-
variates replaces unconditional prediction. Absolute values
of standardized regression coefficients (STDBETA or β^

j ,)
were used for comparing and ranking the variables by
their importance in prediction. The standardized regres-
sion coefficient of a variable Xj is the natural logarithm of
the hazard ratio between two patients who differ in Xj by
1 SD (ceteris paribus), and can be calculated as β^jSD(Xj).
Standardized coefficients were then visually compared by
depicting Ŝ36 and S^
exp β^

jð Þ
36 , which are the average 36 months
overall survival rate and the estimated 36 months overall
survival probability in a subject whose value of Xj differs
from the mean of Xj by 1 SD, respectively.
To further estimate the predictive accuracy of the
above-described modeling algorithm, we performed the
same analyses on the basis of 21 pseudo genes which were
obtained by permuting the full block of the original AID/
APOBEC-associated 21-gene data set, preserving the dis-
tributions and correlation structure within those genes. As
outcome, no models could be built for pseudo AID/APO-
BEC using both ridge and LASSO penalties with respect
to OS and PFS; when combined with clinicopathological
variables, pseudo AID/APOBEC did not improve the pre-
dictive accuracy and discrimination ability of clinicopatho-
logical variables. This provides evidence that the applied
modeling algorithm is robust against falsely identifying
any relevance of randomly selected gene sets.
Correlation coefficients were calculated by Pearson's
correlation for log2 transformed values using SPSS;
Bonferroni-Holm method was used as multiple-testing
correction. P-values ≤ 0.05 were considered as indicating
statistical significance.
Group differences were assessed by two-way analysis
of variance (ANOVA) and Tukey's post hoc test.
Expression profiling of signature-associated genes in
ovarian cancer cell lines using the published microarray-
based data sets
We examined the expression profiles of genes compris-
ing the AID/APOBEC signature across previously
published microarray data sets using the GENEVESTI-
GATOR platform. GENEVESTIGATOR is a manually
curated web-based analysis platform for publicly avail-
able transcriptomic data sets [59, 60]. For analysis, we
selected data sets from the Affymetrix Human Genome
U133 Plus 2.0 Array platform; out of a total of 54037 ar-
rays, we selected data attributed to ovarian cancer cell
lines applying the filter “Cell Lines_Pathological Cell
Lines_Neoplastic Cell Lines_Ovary_All”; this selection
included 149 arrays. The expression values (log2 trans-
formed) were exported from GENEVESTIGATOR for
follow-up clustering and statistical analyses. Clustering
analysis and follow-up graphical representation was per-
formed using Cluster 3.0 and Java TreeView programs.
Analysis of signature-associated, co-expressed genes
using the published microarray-based data sets
For the in silico identification of genes showing co-
regulation with the top candidate genes ranked within
the combined model (ridge) by maximal impact to the
prognostic effect (our heuristic solution is to use the
cutpoint at STDBETA ≥ |0.15|), we used the GENEVES-
TIGATOR search engine. The top candidate genes sub-
jected to GENEVESTIGATOR-based analysis were
designated in the text below as target genes. Members of
the APOBEC3 subfamily exhibit high sequence homolo-
gies. We checked the specificity of Affymetrix probes
covering the APOBEC3 members using BLAST and
ensured that the eligible Affymetrix probe set (ID
204205_at) for APOBEC3G is highly specific, whereas
the probe set 214995_s_at is cross-reactive with APO-
BEC3F and the probe set 215579_at does not recognize
APOBEC3G. This is in line with previously made con-
clusions [13]. The specific APOBEC3G probe set was
used in GENEVESTIGATOR-based analysis. For the
GENEVESTIGATOR-based analysis the following inclu-
sion criteria were applied: (i) we selected data from the
Affymetrix Human Genome U133 Plus 2.0 Array plat-
form; (ii) from a total of 709 arrays of EOC, only those
with annotated FIGO stage (I-IV) were selected (n =
538); (iii) only those target genes were subjected for ana-
lysis which showed detectable microarray expression
based on the normalized signal intensity in ovarian car-
cinoma tissues; (iv) analysis was restricted to samples
with lowest (10th percentile as threshold) and highest
(90th percentile as threshold) target gene expression
levels (n = 106 selected, Additional file 1: Figure S1); the
applied sample selection strategy leads to the exclusion
of those genes which show co-expression with the target
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gene purely based on the non-modulated expression pat-
terns. Additionally, to ensure that changes in target gene
expression across the pre-selected tumor samples within
both groups are caused by intrinsic gene regulation and
not by potential differences in sample quality, a correl-
ation analysis was done between 45 HKGs demonstrat-
ing high homogeneity with correlation coefficients
> 0.99 (Additional file 1: Figure S2). Next, the lists of the
top 50 co-expressed probe sets for each target gene,
ranked according to the Pearson correlation coefficient,
were exported for further analysis; a combined gene list
has been created covering the co-expressed genes of all
individual target probe sets (named as mixed list below).
The content of the mixed list thus reflects the combined
input of the multigene signature accounting for/mimick-
ing the mutual interconnections between the individual
genes. The Ingenuity Pathway Analysis (IPA) tool was
used to assign the co-regulated genes to common bio-
logical pathways, biological functions and/or diseases as
well as upstream regulating molecules [61]. The IPA
Core analysis included the following categories: (i) Ca-
nonical Pathways, (ii) Functional Annotations, and (iii)
Upstream Regulators. The significance of the association
between each gene list and a canonical pathway was
measured by right-tailed Fisher’s exact test. As a result, a
p-value was obtained, determining the probability that
the association between the genes from our data set and
a Canonical Pathway/Functional Category/Upstream
Regulator can be explained by chance alone. The top
ranking was based on the p-value. Only significant out-
comes (p < 0.05) were taken for follow-up analyses. For
alignment of the IPA-derived large-scale data sets, data
mining and data visualization the Spotfire software was
used [62]. Given the complexity of the follow-up ana-
lyses, various approaches were applied. We present
herein two algorithms. (I) The top 10 output results
(herein designated as the 10-top-output_mixed) were
ranked by the corresponding IPA-derived p-values using
the mixed list as input data. Subsequently, the position
of each 10-top-output_mixed candidate was assessed
within the individual target-associated gene list (outpu-
t_individual). Of particular interest were those which ap-
peared in both the 10-top-output_mixed and at least
one of the 10-top-output_individual. (II) The output_-
mixed results were aligned with the output_individual
results searching for the strongest overlap and meaning
the mandatory presence in output_mixed and the max-
imal number of the output_individual (e.g. 5 out of 5 > 4
out of 5 > 3 out of 5; named as output_overlap). Subse-
quently, the 10-top-output_overlap was ranked by the
IPA-derived p-values of the output_mixed results. The
unweighted pair group method with arithmetic mean
was used as clustering method with Euclidean distance
measure and average value as ordering weight.
Study approval
The study was approved in accordance to the require-
ments of the ethical committees of the individual institu-
tions participating in OVCAD (EK207/2003, ML2524,
HEK190504, EK366, EK260). Informed consent for the
scientific use of biological material was obtained from all
patients in accordance with the requirements of the
ethics committees of the institutions involved; the
herein participating OVCAD partners include Depart-
ment of Gynecology, European Competence Center
for Ovarian Cancer at Campus Virchow Klinikum,
Charité – Medical University Berlin (Berlin, Germany),
Division of Gynecological Oncology, Department of
Obstetrics and Gynecology, Universitaire Ziekenhuizen
Leuven, Katholieke Universiteit Leuven (Leuven, Belgium),
Department of Obstetrics and Gynecology, Medical
University of Vienna (Vienna, Austria), and Department
of Gynecology, University Medical Center Hamburg -
Eppendorf (Hamburg, Germany).
Results
A multigene signature approach to assess the patient-
specific transcriptional profiles in the context of the
clinical relevance
The selection of genes composing the multigene signa-
ture is knowledge- and biology-driven. Our expert-
designed gene signature is thereby influenced by previ-
ous published work and disease relevance, and in this
sense is biased towards previous knowledge; importantly,
this selection is not based on pre-tested prognostic im-
pact in our study cohort and thereby does not lead to a
real bias. This approach represents relatively new way of
addressing the pathophysiological relevance of transcrip-
tional profiles and methodologically has indisputable ad-
vantage of the real-time PCR-based analysis that
ultimately provides results which do not need further
methodological validation. It is an appropriate strategy
of choice for low-level expressed genes and for genes
with high sequence similarity which is truly relevant for
AID and APOBEC3 subfamily, respectively. Further-
more, considering the complex cellular composition of
ovarian cancer tissue and the current limited knowledge
linking the cell type-specific expression patterns of AID
and APOBECs with their functionality under diseased
conditions, we included all members of the AID/APO-
BEC family, regardless of other potential ways of their
regulation besides those on the transcriptional levels.
The applied gene signature includes the entire AID/
APOBEC family consisting of AID (AICDA), APOBEC1,
APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APO-
BEC3D, APOBEC3F, APOBEC3G, APOBEC3H, and
APOBEC4; PTPRC (also known as CD45), PAX5 (also
known as BSAP), CD23, NUGGC (also known as SLIP-
GC), and PRDM1 (also known as BLIMP1), ID2 and ID3
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were added accounting for ovarian cancer tissue infiltrat-
ing immune cells, B-cell biology and transcriptional con-
trol of AID, respectively [17, 63, 64]; the estrogen
receptors ESR1 and ESR2 were included given the
hormone-dependent nature of the analyzed tumor type
and the potential involvement of estrogen in AID regula-
tion [39]; DPPA3 (also known as STELLA) and NANOG
are pluripotency-associated genes whose expression was
shown to be linked to the AID functional activity [7, 65];
XRCC5 (also known as KU80) and XRCC6 (also known
as KU70) are involved in DNA repair mechanism
downstream of AID [66]. In sum, the gene panel in-
cludes B-cell identity markers, AID/APOBEC family
members, genes involved in their regulation, and their
functional co-factors or target genes (n = 24). Gene
names, Gene ID, short functional description from
NCBI, synonyms and accession numbers are provided in
Additional file 1: Table S3.
Univariate associations of the individual gene expression-
derived variables and the clinicopathological parameters
with overall and progression free survival
To determine the clinical relevance of the gene expres-
sion data sets of each individual gene of the signature
and of the clinicopathological parameters, we first used
the classical Cox regression analysis strategy whereby
the values were aligned with OS and PFS. Two genes
showed statistically significant associations with OS,
namely AID (HR = 1.18, 95 % CI: 1.04–1.33, p = 0.008)
and ID3 (HR = 1.36, 95 % CI: 1.12–1.64, p = 0.002), as es-
timated by univariate Cox regression analysis and sum-
marized in Additional file 1: Table S4. Among clinical
risk factors, five variables were associated with OS,
namely age (HR = 1.03, 95 % CI: 1.01–1.06, p = 0.011),
FIGO stage (HR = 1.83, 95 % CI: 1.02–3.29, p = 0.044),
grading (HR = 2.10, 95 % CI: 1.03–4.31, p = 0.042), peri-
toneal carcinomatosis (HR = 4.17, 95 % CI: 1.78–9.78,
p = 0.001), and residual disease (HR = 1.98, 95 % CI:
1.15–3.44, p = 0.014; Additional file 1: Table S4). With
respect to PFS, no significant associations with the gene
expression-derived variables were observed (Additional
file 1: Table S4). Three clinical variables showed a strong
association with PFS: FIGO stage (HR = 2.33, 95 % CI:
1.53–3.54, p < 0.001), peritoneal carcinomatosis (HR =
3.88, 95 % CI: 2.27–6.61, p < 0.001) and residual disease
(HR = 1.95, 95 % CI: 1.29–2.94, p = 0.002). APOBEC1,
APOBEC2 and DPPA3 mRNAs were not expressed or
expressed at the detection limit in the ovarian cancer tis-
sues of the herein investigated cohort of patients and
therefore those variables were excluded from the univar-
iate Cox regression and all subsequent analyses. Thus,
the final number of the gene profiling-derived variables
included to the follow-up analyses was equal to n = 21.
Of note, the follow-up statistical models using Cox re-
gression with ridge and LASSO penalties are not based
on the pre-selection of variables according to their sig-
nificance estimated by univariate Cox regression
analysis.
We further performed a correlation analysis for
profiling-derived variables. As summarized in Additional
file 1: Table S5 a strong correlation (r > 0.6; p < 0.001)
was found between PTPRC/CD45 and APOBEC3 family
members such as A3C, A3D, A3G, and A3H as well as
NUGGC and PRDM1; between APOBEC3D and both
APOBEC3G and APOBEC3H, XRCC6/Ku70, NUGGC,
and PRDM1; between ID2 and ID3; between XRCC6/
Ku70 and XRCC5/Ku80 as well as APOBEC3D, ID2 and
ID3; between PAX5 and FCER2; between NANOG and
XRCC6/Ku70 and XRCC5/Ku80; between PRDM1 and
ID3, XRCC6/Ku70, XRCC5/Ku80, and NUGGC. In re-
spect of AID, the strongest correlation was found with
PTPRC/CD45 (r = 0.521; p < 0.001). ESR1 and ESR2 did
not show significant correlation with any other gene of
the multigene signature.
Prognostic models for OS and PFS
Using Cox regression with ridge and LASSO penalties,
we developed multivariable models for evaluating patient
prognosis and for stratifying patients into risk groups.
Calculations were done for three sets of explanatory var-
iables: (i) using the six clinicopathological variables
(Clinics), (ii) using the gene profiling-derived AID/APO-
BEC variables (AID/APOBEC), and (iii) combining clin-
ical and multigene-derived variables (Combined). The
results for the multivariable ridge models are summa-
rized in Tables 2 and 3 and Additional file 1: Table S6.
The clinicopathological variables-based model predicts
both OS (PEV = 8.8 %, c-index = 0.69, p < 0.001) and PFS
(PEV = 17.0 %, c-index = 0.68, p < 0.001). The AID/APO-
BEC model showed moderate predictive accuracy and
discrimination for OS (PEV = 2.5 %, c-index = 0.59, p =
0.025). The combined model had the highest predictive
accuracy with respect to OS (PEV = 11.1 %, c-index =
0.7, p < 0.001). According to their standardized regres-
sion coefficients, the following five genes proved most
important for prediction within the AID/APOBEC
model: ID3, AID, APOBE3G, PTPRC/CD45, and ESR1
(Table 3). Among the covariates within the combined
model, ID3 emerged as the prognostically most import-
ant variable for OS, exceeding the clinical risk factors
such as peritoneal carcinomatosis or age. Together with
ID3, PTPRC/CD45, AID, and APOBEC3G showed high
importance for survival prediction standing ahead of the
clinical risk factors such as grading and histology
(Table 3, Fig. 2).
Patients were sub-divided into low, intermediate, and
high risk groups according to their cross-validated
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Table 2 Comparative analysis of multivariable models (ridge) for prognostication of OS and PFS
OS PFS
PEV % c-index P PEV % c-index P
Clinics 8.77 0.69 <0.001 17.0 0.68 <0.001
AID/APOBEC 2.53 0.59 0.025 n.a. n.a. n.a.
Combined 11.13 0.70 <0.001; 0.021* 13.6 0.65 <0.001; 0.320*
Cross-validated performance assessment of Cox regression models (ridge) by proportion of explained variation (PEV), concordance index (c-index) and p-value.
Models were developed using (i) clinicopathological variables designated as Clinics; (ii) AID/APOBEC multigene-based variables designated as AID/APOBEC; (iii)
their combination designated as Combined
* p-value for added value of AID/APOBEC on top of Clinics in bivariable models with cross-validated predictors
Table 3 Relative importance of individual variables in multivariable models (ridge) for OS
Clinics Combined
Pos. Variables beta HR STDBETA Pos. Variables beta HR STDBETA
1. Peritoneal carcinomatosis 0.83 2.30 0.38 1. ID3 0.30 1.35 0.52
2. Age 0.02 1.02 0.27 2. Peritoneal carcinomatosis 1.05 2.86 0.48
3. Histology 0.58 1.79 0.19 3. Age 0.03 1.03 0.40
4. FIGO stage 0.48 1.62 0.18 4. PTPRC (CD45) 0.19 1.21 0.34
5. Residual disease 0.37 1.45 0.17 5. AICDA 0.14 1.15 0.33
6. Grading 0.34 1.41 0.15 6. APOBEC3G −0.19 0.83 −0.31
AID/APOBEC 7. Grading 0.53 1.70 0.23
Pos. Variables beta HR STDBETA 8. Histology 0.67 1.96 0.22
1. ID3 0.18 1.19 0.30 9. ID2 −0.12 0.89 −0.22
2. AICDA 0.09 1.09 0.21 10. FIGO stage 0.50 1.64 0.18
3. APOBEC3G −0.11 0.89 −0.19 11. Residual disease 0.36 1.44 0.17
4. PTPRC (CD45) 0.08 1.08 0.14 12. NUGGC −0.08 0.92 −0.16
5. ESR1 −0.06 0.94 −0.11 13. PAX5 −0.06 0.94 −0.16
6. PRDM1 0.06 1.06 0.10 14. ESR1 −0.08 0.92 −0.16
7. APOBEC3B 0.05 1.05 0.09 15. ESR2 0.04 1.04 0.14
8. XRCC5 (Ku80) −0.06 0.95 −0.07 16. APOBEC3A −0.07 0.93 −0.14
9. APOBEC3A −0.03 0.97 −0.07 17. APOBEC3C −0.10 0.91 −0.11
10. APOBEC3C −0.06 0.95 −0.06 18. APOBEC3D 0.06 1.06 0.09
11. PAX5 −0.02 0.98 −0.06 19. APOBEC3F 0.06 1.06 0.07
12. ID2 −0.03 0.97 −0.05 20. XRCC6 (Ku70) 0.05 1.05 0.06
13. XRCC6 (Ku70) 0.04 1.04 0.05 21. NANOG 0.04 1.04 0.06
14. FCER2 −0.02 0.98 −0.05 22. APOBEC3H 0.03 1.03 0.06
15. APOBEC3F 0.03 1.03 0.03 23. PRDM1 0.03 1.03 0.04
16. ESR2 0.01 1.01 0.03 24. APOBEC3B 0.02 1.02 0.03
17. APOBEC3H −0.01 0.99 −0.01 25. APOBEC4 0.01 1.01 0.02
18. APOBEC4 0.00 1.00 0.01 26. XRCC5 (Ku80) −0.02 0.98 −0.02
19. APOBEC3D 0.00 1.00 −0.01 27. FCER2 0.00 1.00 0.00
20. NUGGC 0.00 1.00 −0.01
21. NANOG 0.00 1.00 −0.01
Within each model, variables are ranked by descending importance as expressed by their absolute standardized regression coefficients. Histology was
encoded as “0” for serous and “1” for non-serous; Peritoneal carcinomatosis was encoded as “0” for no and “1” for yes; Grading was encoded as “0” for
Grade 1 and 2 and “1” for Grade 3; Residual disease was encoded as “0” for no and “1” for yes; beta, regression coefficient (log hazard ratio); HR, hazard
ratio; STDBETA, standardized regression coefficients. By multivariate modeling with penalized likelihood, the multivariate-adjusted HR shows the direction
and magnitude of prognostic effect if adjusted for other variables. Ridge regression shifts the HR towards the value of 1.0 to avoid overestimation bias
and to decrease variance in models with many variables
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predictors for OS based on the ridge model. Figure 3
shows the corresponding Kaplan-Meier graphs. The
combined model showed statistically significant differ-
ences between the risk groups (log-rank test: p < 0.001)
giving major improvement of patient stratification. With
respect to PFS, the combination of gene expression data
sets with the clinical variables did not result in improved
patient stratification in comparison to the clinicopatho-
logical variables-based model (Fig. 3). Importantly, the
results of the second regularization method (LASSO)
were in line with those described above and indicated
similar predictive abilities with respect to OS by the
clinicopathological variables-based model (PEV =
7.54 %, c-index = 0.67, p < 0.001), by the AID/APOBEC
multigene-based model (PEV = 5.76 %, c-index = 0.64,
p < 0.001), and superior performance of the combined
model (PEV = 10.80 %, c-index = 0.70, p < 0.001) (Add-
itional file 1: Tables S7-S9, Additional file 1: Figure
S3). The corresponding Kaplan-Meier graphs for OS
and PFS using the LASSO penalization are shown in
Additional file 1: Figure S4.
Expression of genes from the AID/APOBEC multigene
signature in ovarian cancer cell lines
Given the complex cellular composition of the ovarian
cancer tissues we assessed the mRNA expression of genes
composing the AID/APOBEC multigene signature by
real-time PCR in four ovarian cancer cell lines such as
A2780, A2780ADR, OVCAR-3, and SK-OV-3. Expression
profiling revealed that the majority of genes were found to
be expressed in at least one of the four examined cell lines
(Additional file 1: Figure S5); of note, among those are the
top genes, which showed the highest impact to the prog-
nostic power of the multivariable model.
We next expanded the scope of expression analysis to
a wider range of ovarian cancer cell lines (n = 55) across
previously published microarray data sets using the
GENEVESTIGATOR platform (Additional file 1: Figure
S6). The analyzed set of cell lines included, among
others, the ovarian cancer cell lines, which had been pre-
viously ranked and sub-grouped by their suitability as
high-grade serous ovarian cancer tumors on the basis of
genomic profiling [67]. With the exception of genes
Fig. 2 Impact of individual variables on survival prediction of the multivariable model (ridge) for OS if predictors are changed by +1 SD. Survival
probabilities are estimated at 36 months of follow-up time. The length of the lines is proportional to the change in prediction in case the value
of the indicated variable changes by +1 SD (left: negative effect; right: positive effect). Variables are ranked according to the absolute changes in
prediction which also corresponds to the order within the combined model (Table 3). Gene profiling variables not used for follow-up analyses are
displayed in grey color
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exhibiting low expression and/or expression at the
microarray detection limit (AICDA, APOBEC1, APO-
BEC3A, PAX5, and PTPRC), the genes composing the
AID/APOBEC multigene signature were expressed in
various cell lines representing the above mentioned sub-
groups. We next applied a hierarchical cluster analysis
on the basis of expression values of the signature genes
across the analyzed cell lines. The resulting two main
clusters for ovarian cancer cell lines accentuate the ex-
pression differences for APOBEC3B, APOBEC3C, and
APOBEC3G as well as of ID2 and ID3 (Additional file 1:
Figure S7).
Systems biology approach linking the gene expression
data sets with the disease-relevant biological pathways
and functions
To define the AID/APOBEC-attributed biological path-
ways potentially associated with the pathogenesis of
ovarian cancer, a systems biology approach was applied
(described in detail in Fig. 1 of study design and in
Methods). The eligible genes from the profiling-derived
candidate genes with the highest impact to the com-
bined prognostic model include AID, APOBEC3G, ESR1,
ID2, ID3, NUGGC, PAX5, and PTPRC/CD45. However,
3 genes were excluded such as NUGGC, since no corre-
sponding probesets do exist on the U133 Plus 2.0 Array,
and AID and PAX5 due to the low mRNA expression
levels in ovarian cancer tissue when detected by micro-
array. Thus, APOBEC3G, ESR1, ID2, ID3, and PTPRC/
CD45 were used as target genes for follow-up analyses.
Next, for each target gene we assessed the co-expressed
genes in ovarian cancer tissues by GENEVESTIGATOR.
The exported gene lists are summarized in Additional
file 1: Tables S10-S14. To assign the co-regulated genes
to common biological pathways, biological functions
and/or diseases as well as upstream regulating molecules
the Ingenuity Pathway Analysis (IPA) tool was used.
Data-driven signature-associated Canonical pathways
Results of the follow-up IPA-based core analysis in re-
spect of the Canonical Pathways are listed in Table 4
(based on the algorithm I, where the priority is given to
the outcome_mixed as specified in Methods). The Ca-
nonical Pathway designated as Hepatic Fibrosis/Hepatic
Stellate Cell Activation was ranked to position 1. Of
note, 8 out of the top 10 canonical pathways derived
Fig. 3 Kaplan-Meier estimates for patient stratification based on the AID/APOBEC model, the clinical model, and the combined one (ridge-based).
Kaplan-Meier curves for OS and PFS are shown giving patients’ stratification into low risk (n = 46, green), intermediate risk (n = 94, red), and high
risk (n = 46, black) groups with the 25th and 75th percentiles serving as thresholds (lower than the 25th percentile indicates low risk). No stable
and well calibrated model for AID/APOBEC was found in respect of PFS, thus only models for Clinics and Combined are shown. P-value of the
log-rank test is indicated
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Table 4 The 10-top-AID/APOBEC signature-linked Canonical Pathways identified by systems biology approach (algorithm I)
Canonical 10-top-output_mixeda Canonical output_individualb Related studiesc
APOBEC3G ESR1 ID2 ID3 PTPRC (CD45)
Pos. Canonical pathways P-value Molecules Pos. Molecules Pos. Molecules Pos. Molecules Pos. Molecules Pos. Molecules Ovarian
Cancer
Others
1 Hepatic Fibrosis /
Hepatic Stellate
Cell Activation
8.32E-08 COL1A1, IGFBP4,
CCR5, FN1, CTGF,
TIMP1, ACTA2,
IL10RA, CCL5,
FAS, EGFR
1 COL1A1,
IGFBP4,
CTGF, TIMP1,
ACTA2, FAS,
EGFR
5 IGFBP4,
FN1
14 CCR5, IL10RA,
CCL5
[79, 80, 98] [81]
2 Altered T Cell and
B Cell Signaling in
Rheumatoid Arthritis
1.51E-06 HLA-DOA, IL15,
TLR8, FCER1G,
CD86, TLR3,
TNFSF13B, FAS
3 HLA-DOA, IL15,
TLR3, TNFSF13B
6 TLR8, FCER1G,
CD86
[83]
3 Antigen Presentation
Pathway
2.40E-05 PSMB9, HLA-DOA,
CIITA, HLA-DPB1,
HLA-DPA1
1 PSMB9, HLA-DOA,
CIITA, HLA-DPB1,
HLA-DPA1
[82, 99]
4 Communication
between Innate
and Adaptive
Immune Cells
2.45E-05 IL15, TLR8, FCER1G,
CD86, CCL5, TLR3,
TNFSF13B
4 IL15, CCL5, TLR3,
TNFSF13B
1 TLR8, FCER1G,
CD86, CCL5
[100]
5 Role of Pattern
Recognition Receptors
in Recognition of
Bacteria and Viruses
3.47E-05 IFIH1, CLEC7A,
TLR8, CASP1,
CCL5, TLR3,
C3AR1
2 IFIH1, CLEC7A,
CASP1, CCL5, TLR3
9 TLR8, CCL5,
C3AR1
[101–103]
6 Allograft Rejection
Signaling
1.35E-04 HLA-DOA, FCER1G,
CD86, HLA-DPB1,
HLA-DPA1, FAS
6 HLA-DOA, HLA-DPB1,
HLA-DPA1
25 FCER1G, CD86 [104]
7 Crosstalk between
Dendritic Cells and
Natural Killer Cells
2.09E-04 CSF2RB, ACTA2,
IL15, CD86,
TLR3, FAS
21 IL15, TLR3 40 ACTA2,FAS 27 CSF2RB, CD86 [105, 106]
8 CCR5 Signaling in
Macrophages
5.25E-04 CCR5, FCER1G,
CCL5, GNG12,
FAS
27 GNG12, FAS 4 CCR5, FCER1G,
CCL5
[107, 108] [109]
9 CD28 Signaling in
T Helper Cells
8.13E-04 PTPRC, HLA-DOA,
FCER1G, CD86,
ITPR1, LCP2
2 PTPRC, FCER1G,
CD86, LCP2
[110, 111]
10 Graft-versus-Host
Disease Signaling
9.12E-04 HLA-DOA, FCER1G,
CD86, FAS
16 FCER1G, CD86 [112]
aIPA nomenclature is used for canonical pathways. The 10-top-output_mixed results are shown; the ranking is based on the corresponding IPA-based p-value; the molecules mapped to the pathway are listed
bPosition of the canonical pathway within the output_individual for each target gene, the corresponding p-value and the molecules mapped to the pathway are indicated. Bold, within the 10-top-output_individual;
Italic, outside the 10-top-output_individual. Empty cell: the corresponding pathway was not significant in output_individual
cLiterature search-based results annotating those canonical pathways in ovarian cancer or other related studies
Svoboda
et
al.BM
C
G
enom
ics
 (2016) 17:643 
Page
12
of
28
from the output_mixed were found in at least one out-
put_individual within the 10-top positions (with p-values
all < 0.05; Table 4). The strongest overlap between the
10-top-output pathways of mixed and individual was ob-
served for APOBEC3G (5/10) and PTPRC/CD45 (5/10)
indicating the strongest contribution from those two
genes; in contrast, no overlap was found for ESR1. Simi-
larly to the algorithm I-derived results, Hepatic Fibrosis/
Hepatic Stellate Cell Activation pathway was as well
ranked to position 1 when the algorithm II was applied,
where the priority is given to the overlap between the
output_mixed and output_individual (Additional file 1:
Table S15). The results of overall alignment illustrated
by the heat map (Additional file 1: Figure S8, A) and by
pie chart (Additional file 1: Figure S9, A) indicate that
the Canonical Pathways attributed to the individual tar-
get genes are mostly diverse among each other but show
a strong overlap with the mixed-attributed Canonical
Pathways. To align the results of herein pathway analysis
with the related studies, we additionally included the ref-
erences to the published studies in the area of ovarian
carcinoma and others (Table 4 and Additional file 1:
Table S15).
Data-driven signature-associated functional annotations
and/or diseases
IPA was further used to align the output gene lists with
the biological functions and/or diseases named as Func-
tional Annotations. Due to affiliation of functional anno-
tations into several functional categories, the broader
IPA classification system, only algorithm II was applied.
Results of the 10-top are shown in Tables 5, 6 and 7 and
include the results of the output_mixed overlaid with 5,
4, or 3 output_individual. We observed the strong over-
lap between mixed and ID2 > PTPRC/CD45 >APO-
BEC3G > ID3 and the minor overlap with ESR1. Within
the top outcomes, the over-representation of the basic
cellular functions with the accents to the cell movement
linked to the immune system and inflammation-driven
diseases was documented. Furthermore, at this categor-
ical level the cancer-related processes appeared (metas-
tasis, triple-negative breast cancer). Additionally, the
total alignment patterns are illustrated by heat map
(Additional file 1: Figure S8, B) and by pie chart
(Additional file 1: Figure S9, B).
Data-driven signature-associated upstream regulators
To include the biological information for the higher-
level overview, the IPA-based analysis for Upstream Reg-
ulators was performed. In this case, both algorithms I
and II were used. The 10-top most significantly over-
represented regulators, when applying algorithm I, were
LPS, IFNalpha, IFNgamma, TGFbeta1, TNF, IL10,
STAT3, IL6, IL13, and tretinoin (Table 8). Of note, 6 out
of 10 regulators derived from the output_mixed were
found in at least one output_individual within the 10-
top positions (with p-values all < 0.05). The strongest
overlap between the 10-top-output_mixed and _individ-
ual was observed for APOBEC3G (4/10) and PTPRC/
CD45 (2/10); in contrast, no overlap was found for
ESR1, thus the observed distribution is similar to the
one described for Canonical Pathways analysis (Table 4).
Complementary, the heat map and pie chart illustrate
the total overlap patterns between output_mixed and
output_individuals (Figures S8, C and S9, C). When ap-
plying the algorithm II, the following additional mole-
cules were identified such as APOE, CD44, TECAM1,
Ifi204, alpha Catenin, INFbeta1, TGFBR1, SPI1, and
CD40 (Additional file 1: Tables S16 and S17).
Discussion
Multigene profiling and survival models
The herein presented study is, to our knowledge, the
first one linking expression of the entire AID/APOBEC
family and interacting genes with clinical outcome with
respect to survival of cancer patients. High efforts are
invested in the field of cancer research to evaluate the
applicability of gene expression for the use in risk pre-
diction; nevertheless, no established standard is available
for the implemented methodology to study gene expres-
sion profiles in the pathophysiology of disease. Different
approaches have certain advantages and disadvantages.
Data-driven approaches using curated microarray ex-
pression data from various studies offer the advantage of
a transcriptome-wide screening, but face a lack of sensi-
tivity for very low-level expressed genes and/or the spe-
cificity for genes with high sequence similarity; the latter
two aspects are fully relevant for AID and APOBEC3
subfamily, respectively, as discussed herein and by others
[13]. A knowledge-driven approach, where the compos-
ition of a gene signature characterizing certain biological
aspects is assembled based on data mining followed by
real-time PCR-based gene expression profiling of clinical
specimens has by definition the advantage of high sensi-
tivity and reproducibility as real-time PCR methodology
is the gold standard in expression profiling. To
maximize the outcome, we applied herein a rational in-
tegration of both approaches.
We structured the study by three consecutive analyt-
ical modules: (i) multigene-based expression profiling,
(ii) statistical modeling for survival prediction and (iii)
delineation of AID/APOBEC-associated gene network(s)
and pathways by applying bioinformatics tools (as sum-
marized in Fig. 1). Each module resulted in novel out-
comes with respect to the pathophysiology of ovarian
cancer; their combination in turn provided an advanta-
geous comprehensive overview. The herein established
study algorithm, named by us as MuSiCO (from
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Table 5 The top-AID/APOBEC signature-linked Functional Annotations identified by systems biology approach (algorithm II; overlap with 5 individual target genes)
Functional Annotation
top-output_mixed_
and_5_individual
Pos. Functional
Annotations
Mixed APOBEC3G ESR1 ID2 ID3 PTPRC (CD45)
P-value Molecules Molecules Molecules Molecules Molecules Molecules
1 proliferation
of cells
1.16E-16 AEBP1, AIF1, ALOX5, AR,
ARMC10, BGN, C3AR1,
CAMK2N1, CASP1, CCL5,
CCR5, CD2, CD47, CD48,
CD84, CD86, CDKN1A,
CIITA, CLEC7A, COL1A1,
COL6A1, COL6A2, CSF2RB,
CTGF, CTSS, CYBB, DKK3,
DLC1, DOCK2, EGFR,
EMILIN1, ENG, EPS8, ESR1,
FAS, FBN1, FCER1G, FN1,
FOXP1, FYB, GBP2, HCK,
HEXB, HLA-DPB1, ID1, ID2,
ID3, IGFBP4, IGFBP7, IL10RA,
IL15, IRF1, ITGAM, ITPR1,
LAIR1, LAMB1, LCP2, LIMA1,
LPAR3, LRIG1, LST1, MEIS1,
MNDA, MTUS1, MUC16,
NID2, NPAS3, NPDC1,
PMEPA1, PMP22, PPAP2A,
PRRX1, PSMB10, PTPRC,
RARRES3, RHBDF1, RHOB,
ROCK2, SAMSN1, SASH3,
SDC2, SNAI2, SOX17,
SPOCK1, SULF2, TIMP1,
TLR3, TNFRSF14, TNFSF13B,
VCAN, ZFP36
ALOX5, CASP1,
CCL5, CIITA,
CLEC7A, CTSS,
GBP2, HLA-DPB1,
IL15, IRF1, ITGAM,
PSMB10, RARRES3,
TLR3, TNFRSF14,
TNFSF13B
AR, ARMC10, CD47,
ESR1, LPAR3, LRIG1,
MEIS1, MUC16,
NPAS3, SOX17
CAMK2N1, CDKN1A,
COL1A1, COL6A1,
COL6A2, CTGF, DLC1,
EGFR, ENG, EPS8, FAS,
FOXP1, HEXB, ID1, ID2,
ID3, IGFBP4, IGFBP7,
LIMA1, MTUS1, NPDC1,
PPAP2A, RHBDF1, RHOB,
SDC2, SNAI2, SULF2,
TIMP1, ZFP36
AEBP1, COL6A2,
DKK3, DLC1,
EMILIN1, FBN1,
FN1, ID1, ID2, ID3,
IGFBP4, ITPR1,
LAMB1, LIMA1,
PMEPA1, PMP22,
PPAP2A, PRRX1,
RHOB, SDC2,
SNAI2, SULF2, VCAN
AIF1, C3AR1, CCL5,
CCR5, CD2, CD48,
CD84, CD86, CSF2RB,
CYBB, DOCK2, FCER1G,
FYB, HCK, IL10RA, LAIR1,
LCP2, LST1, MNDA, PTPRC,
SAMSN1, SASH3
IPA nomenclature was used for Functional Annotations. The top-output_mixed_and_5 individual results are shown; the ranking is based on the corresponding IPA-based p-value of the output_mixed; the molecules
mapped to the Functional Annotation are listed
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Table 6 The top-AID/APOBEC signature-linked Functional Annotations identified by systems biology approach (algorithm II; overlap with 4 individual target genes)
Functional Annotations-top-output_mixed_and_4_individual
Pos. Functional
Annotations
Mixed APOBEC3G ESR1 ID2 ID3 PTPRC (CD45)
P-value Molecules Molecules Molecules Molecules Molecules Molecules
1 arthritis 1.53E-17 AIF1, ALOX5, AR, BGN,
C3AR1, CASP1, CCL5,
CCR5, CD86, CDH11,
CDKN1A, CIITA,
COL6A1, CSF2RB,
CTSS, FAS, FCER1G,
FCGRT, FN1, FSTL1,
GBP2, GZMA, HCK,
HLA-DOA, HLA-DPA1,
HLA-DPB1, IGFBP4,
IGFBP7, IL10RA, IL15,
IRF1, ITGAM, ITPR1,
JAM3, LST1, MS4A6A,
PSMB9, PTPRC, SAMD9L,
SDC2, SNAI2, SPOCK1,
TAGAP, TIMP1, TLR3,
TNFSF13B, ZFP36
ALOX5, CASP1,
CCL5, CIITA, CTSS,
GBP2, HLA-DOA,
HLA-DPA1, HLA-DPB1,
IL15, IRF1, ITGAM,
MS4A6A, PSMB9, SAMD9L,
TAGAP, TLR3, TNFSF13B
CDH11, CDKN1A,
COL6A1, FAS, FCGRT,
IGFBP4, IGFBP7, SDC2,
SNAI2, TIMP1, ZFP36
BGN, CDH11, FN1,
IGFBP4, ITPR1, JAM3,
SDC2, SNAI2, SPOCK1
AIF1, C3AR1, CCL5,
CCR5, CD86, CSF2RB,
FCER1G, GZMA, HCK,
IL10RA, LST1, MS4A6A,
PTPRC
2 cell death of immune
cells
8.52E-15 CASP1, CCL5, CCR5, CD2,
CD47, CD86, CDKN1A,
CIITA, COL1A1, CSF2RB,
CYBB, EGFR, ESR1, EYA2,
FAS, FCER1G, FN1, GIMAP4,
GZMA, HCK, ID2, ID3, IFIH1,
IL15, IRF1, ITGAM, ITPR1,
LAIR1, LRIG1, MEIS1, PTPRC,
SNAI2, TIMP1, TLR3,
TNFSF13B
CASP1, CCL5,
CIITA, IFIH1, IL15,
IRF1, ITGAM, TLR3,
TNFSF13B
CD47, ESR1,
EYA2, LRIG1,
MEIS1
CDKN1A, COL1A1,
EGFR, FAS, ID2, ID3,
SNAI2
CCL5, CCR5, CD2,
CD86, CSF2RB, CYBB,
FCER1G, GIMAP4, GZMA,
LAIR1, PTPRC
3 rheumatoid arthritis 2.2E-13 AIF1, ALOX5, BGN, C3AR1,
CCL5, CCR5, CD86, CDH11,
CIITA, CSF2RB, FCGRT, GBP2,
GZMA, HCK, HLA-DOA,
HLA-DPA1, HLA-DPB1,
IGFBP4, IGFBP7, IL10RA,
ITPR1, JAM3, LST1, MS4A6A,
PSMB9, PTPRC, SAMD9L,
SDC2, SNAI2, SPOCK1,
TAGAP, TIMP1, TLR3,
TNFSF13B, ZFP36
ALOX5, CCL5, CIITA, GBP2,
HLA-DOA, HLA-DPA1,
HLA-DPB1, MS4A6A, PSMB9,
SAMD9L, TAGAP, TLR3,
TNFSF13B
CDH11, FCGRT,
IGFBP4, IGFBP7,
SDC2, SNAI2,
TIMP1, ZFP36
BGN, CDH11, IGFBP4,
ITPR1, JAM3, SDC2,
SNAI2, SPOCK1
AIF1, C3AR1, CCL5,
CCR5, CD86, CSF2RB,
GZMA, HCK, IL10RA,
LST1, MS4A6A, PTPRC
4 apoptosis 2.9E-12 AIF1, ALOX5, ANTXR2,
APOL6, AR, ARMC10, BGN,
CASP1, CCL5, CCR5, CD2,
CD47, CD48, CD53, CDH11,
CDKN1A, CIITA, COL1A1,
CSF2RB, CTGF, CTSS, CYBB,
DKK3, DLC1, EGFR, ENG,
ESR1, EVA1C, EYA2, FAS,
ALOX5, APOL6, CASP1, CCL5,
CIITA, CTSS, EVA1C, IFIH1,
IL15, IRF1, ITGAM, TLR3,
TNFSF13B, XAF1
ANTXR2, CDKN1A,
COL1A1, CTGF, DLC1,
EGFR, ENG, FAS,
FOXP1, HEXB, ID1, ID2,
ID3, IGFBP4, IGFBP7,
RHOB, SDC2, SGPP1,
SNAI2, SULF2, TIMP1,
ZFP36
BGN, DKK3, DLC1,
FBN1, FN1, FSTL1,
ID1, ID2, ID3, IGFBP4,
ITPR1, PMEPA1,
PMP22, RHOB, SDC2,
SNAI2, SPOCK1, SULF2
CCL5, CCR5, CD2, CD48,
CD53, CSF2RB, CYBB,
FCER1G, GZMA, HCK,
LAIR1, MNDA, PTPRC
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Table 6 The top-AID/APOBEC signature-linked Functional Annotations identified by systems biology approach (algorithm II; overlap with 4 individual target genes) (Continued)
FBN1, FCER1G, FN1, FOXP1,
FSTL1, GIMAP4, GZMA, HCK,
HEXB, ID1, ID2, ID3, IFIH1,
IGFBP4, IGFBP7, IL15, IRF1,
ITGAM, ITPR1, LAIR1, LRIG1,
MNDA, MUC16, PMEPA1,
PMP22, PTPRC, RHOB,
SDC2, SGPP1, SNAI2, SOX17,
SPOCK1, SULF2, TIMP1, TLR3,
TNFRSF14, TNFSF13B, VCAN,
XAF1, ZFP36
5 necrosis 1.36E-11 ALOX5, ANTXR2, AR, ARMC10,
BGN, CASP1, CCL5, CCR5, CD2,
CD47, CD48, CD86, CDH11,
CDKN1A, CIITA, COL1A1,
COL6A1, CSF2RB, CTGF, CTSS,
CYBB, DKK3, DPYD, EGFR, ENG,
ESR1, EVA1C, EYA2, FAS,
FCER1G, FN1, FSTL1, GIMAP4,
GZMA, HCK, =ID1, ID2, ID3,
IFIH1, IGFBP4, IGFBP7, IL15,
IRF1, ITGAM, ITPR1, LAIR1,
LRIG1, MEIS1, MUC16,
PMEPA1, PMP22, PTPRC,
RHOB, ROCK2, SDC2, SGPP1,
SNAI2, SOX17, SPOCK1, SULF2,
TIMP1, TLR3, TNFRSF14,
TNFSF13B, VCAN, XAF1
ALOX5, CASP1, CCL5, CIITA,
CTSS, DPYD, EVA1C, IFIH1,
IL15, IRF1, ITGAM, TLR3,
TNFRSF14, TNFSF13B, XAF1
ANTXR2, CDKN1A,
COL1A1, COL6A1,
CTGF, EGFR, ENG, FAS,
ID1, ID2, ID3, IGFBP4,
IGFBP7, RHOB, ROCK2,
SDC2, SGPP1, SNAI2,
SULF2, TIMP1
BGN, DKK3, FN1, FSTL1,
ID1, ID2, ID3, IGFBP4,
ITPR1, PMEPA1, PMP22,
RHOB, SDC2, SNAI2,
SPOCK1, SULF2
CCL5, CCR5, CD2, CD48,
CD86, CSF2RB, CYBB,
FCER1G, GIMAP4, GZMA,
HCK, LAIR1, PTPRC
IPA nomenclature was used for Functional Annotations. Since analysis for the 10-top-output_mixed_and_5 individual revealed only one functional annotation, the results of the top-output_mixed_and_4 individual are
additionally shown. The ranking is based on the corresponding IPA-based p-value of the output_mixed; the molecules mapped to the Functional Annotation are listed
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Table 7 The 10-top-AID/APOBEC signature-linked Functional Annotations identified by systems biology approach (algorithm II; overlap with 3 individual target genes)
Functional Annotations-10-top-output_mixed_and_3_individual
Pos. Functional
Annotations
Mixed APOBEC3G ESR1 ID2 ID3 PTPRC (CD45)
P-value Molecules Molecules Molecules Molecules Molecules Molecules
1 Rheumatic
Disease
1.66E-18 ACTA2, AIF1, ALOX5, AR, BGN, C3AR1,
CASP1, CCL5, CCR5, CD86, CDH11,
CDKN1A, CIITA, COL1A1, COL6A1,
CSF2RB, CTSS, FAS, FBN1, FCER1G,
FCGRT, FN1, FSTL1, GBP2, GZMA,
HCK, HLA-DOA, HLA-DPA1, HLA-DPB1,
IGFBP4, IGFBP7, IL10RA, IL15, IRF1,
ITGAM, ITPR1, JAM3, LST1, MS4A6A,
PSMB9, PTPRC, SAMD9L, SDC2, SNAI2,
SPOCK1, TAGAP, TIMP1, TLR3, TLR8,
TNFSF13B, ZFP36
ACTA2, CDH11, CDKN1A,
COL1A1, COL6A1, FAS,
FCGRT, IGFBP4, IGFBP7,
SDC2, SNAI2, TIMP1,
ZFP36
BGN, CDH11,
FBN1, FN1,
IGFBP4, ITPR1,
JAM3, SDC2,
SNAI2, SPOCK1
AIF1, C3AR1, CCL5,
CCR5, CD86, CSF2RB,
FCER1G, GZMA, HCK,
IL10RA, LST1, MS4A6A,
PTPRC, TLR8
2 cell movement
of leukocytes
8.68E-17 AIF1, ALOX5, AR, BGN, C3AR1, CASP1,
CCL5, CCR5, CD2, CD47, CD48, CD86,
CDKN1A, CIITA, COL1A1, CTGF, CTSS,
CYBB, DOCK2, EGFR, ENG, EPS8, ESR1,
FAS, FCER1G, FN1, FYB, HCK, IL10RA,
IL15, ITGAM, JAM3, LCP2, PTPRC,
RHOB, ROCK2, TIMP1, TLR3, TNFRSF14,
TNFSF13B
ALOX5, CASP1, CCL5,
CIITA, CTSS, IL15, ITGAM,
TLR3, TNFSF13B
CDKN1A, COL1A1, EGFR,
ENG, EPS8, FAS, RHOB,
ROCK2, TIMP1
AIF1, C3AR1, CCL5, CCR5,
CD2, CD48, CD86, CYBB,
DOCK2, FCER1G, FYB, HCK,
IL10RA, LCP2
3 quantity of
leukocytes
1.51E-16 ALOX5, C3AR1, CCL5, CCR5, CD47,
CD48, CD84, CD86, CDKN1A, CIITA,
CLEC7A, CSF2RB, CTSS, CYBB, DKK3,
DOCK2, ESR1, FAS, FCER1G, FOXP1,
FYB, HCK, HEXB, ID1, ID2, IL10RA, IL15,
IRF1, ITGAM, JAM3, LAIR1, LCP2, MEIS1,
PSMB10, PSMB9, PTPRC, SAMSN1, SASH3,
SLA, SNAI2, TIMP1, TLR3, TNFSF13B, ZFP36
ALOX5, CCL5, CIITA, CLEC7A,
CTSS, IL15, IRF1, ITGAM,
PSMB10, PSMB9, TLR3,
TNFSF13B
CDKN1A, FAS, FOXP1,
HEXB, ID1, ID2, SNAI2,
TIMP1, ZFP36
C3AR1, CCL5, CCR5, CD48,
CD84, CD86, CSF2RB, CYBB,
DOCK2, FCER1G, FYB, HCK,
IL10RA, LAIR1, LCP2, PTPRC,
SAMSN1, SASH3, SLA
4 cell movement
of myeloid cells
4.14E-13 AIF1, ALOX5, AR, C3AR1, CASP1, CCL5,
CCR5, CD2, CD47, CD48, CDKN1A, COL1A1,
CTGF, CTSS, CYBB, DOCK2, EGFR, ENG, FAS,
FCER1G, FN1, HCK, IL15, ITGAM, JAM3,
PTPRC, RHOB, ROCK2, TLR3
ALOX5, CASP1, CCL5,
CTSS, IL15, ITGAM, TLR3
CDKN1A, COL1A1,
EGFR, ENG, FAS, RHOB,
ROCK2
AIF1, C3AR1, CCL5, CCR5,
CD2, CD48, CYBB, DOCK2,
FCER1G, HCK
5 cell movement
of phagocytes
9.33E-13 AIF1, ALOX5, AR, C3AR1, CASP1, CCL5,
CCR5, CD47, CD86, CDKN1A, COL1A1,
CTGF, CTSS, CYBB, DOCK2, EGFR, ENG,
EPS8, FAS, FCER1G, FN1, HCK, IL10RA,
IL15, ITGAM, JAM3, RHOB, TIMP1, TLR3
ALOX5, CASP1, CCL5,
CTSS, ITGAM, TLR3
CDKN1A, COL1A1, EGFR,
ENG, EPS8, FAS, RHOB,
TIMP1
AIF1, C3AR1, CCL5, CCR5,
CD86, CYBB, DOCK2,
FCER1G, HCK, IL10RA
6 cell death 7.48E-11 AIF1, ALOX5, ANTXR2, APOL6, AR, ARMC10,
BGN, CASP1, CCL5, CCR5, CD2, CD47, CD48,
CD53, CD86, CDH11, CDKN1A, CIITA, COL1A1,
COL6A1, CSF2RB, CTGF, CTSS, CYBB, DKK3,
DLC1, DPYD, EGFR, ENG, ESR1, EVA1C, EYA2,
FAS, FBN1, FCER1G, FN1, FOXP1, FSTL1,
GIMAP4, GZMA, HCK, HEXB, ID1, ID2, ID3,
IFIH1, IGFBP4, IGFBP7, IL15, IRF1, ITGAM,
ALOX5, APOL6, CASP1, CCL5,
CIITA, CTSS, DPYD, EVA1C,
IFIH1, IL15, IRF1, ITGAM,
TLR3, TNFRSF14, TNFSF13B,
XAF1
ANTXR2, CDKN1A, COL1A1,
COL6A1, CTGF, DLC1, EGFR,
ENG, FAS, FOXP1, HEXB, ID1,
ID2, ID3, IGFBP4, IGFBP7,
RHOB, ROCK2, SDC2, SGPP1,
SNAI2, SULF2, TIMP1, ZFP36
AIF1, CCL5, CCR5, CD2,
CD48, CD53, CD86,
CSF2RB, CYBB, FCER1G,
GIMAP4, GZMA, HCK,
LAIR1, LCP2, MNDA, PTPRC
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Table 7 The 10-top-AID/APOBEC signature-linked Functional Annotations identified by systems biology approach (algorithm II; overlap with 3 individual target genes)
(Continued)
ITPR1, LAIR1, LCP2, LRIG1, MEIS1, MNDA,
MUC16, PMEPA1, PMP22, PTPRC, RHOB,
ROCK2, SDC2, SGPP1, SNAI2, SOX17,
SPOCK1, SULF2, TFEC, TIMP1, TLR3,
TNFRSF14, TNFSF13B, VCAN, XAF1,
ZFP36
7 metastasis 1.05E-10 ACTA2, AR, CASP1, CD47, CD86,
CDKN1A, CTGF, CYBB, EGFR, ESR1,
FN1, FOXP1, ID1, ID2, ID3, IGFBP7,
IL15, IRF1, JAM3, MEIS1, NID2,
PAPSS2, PRRX1, RAB31, RHOB,
TIMP1, TLR8, VCAN
AR, CD47,
ESR1, MEIS1
ACTA2, CDKN1A, CTGF, EGFR,
FOXP1, ID1, ID2, ID3, IGFBP7,
PAPSS2, RAB31, TIMP1
FN1, ID1, ID2,
ID3, JAM3,
PRRX1
8 triple-negative
breast cancer
1.15E-10 AR, CDH11, CDKN1A, CTGF, DLC1, EGFR,
EPS8, ESR1, FAS, HCK, IRF1, LAMB1,
TIMP1, WFDC2
AR, ESR1,
WFDC2
CDH11, CDKN1A, CTGF, DLC1,
EGFR, EPS8, FAS, TIMP1
CDH11, DLC1,
LAMB1
9 binding of cells 1.52E-10 AR, BGN, CCL5, CCR5, CD2, CD47, CD48,
CD84, CD86, CLEC7A, CSF2RB, ENG, FAS,
FN1, FYB, HCK, HS3ST1, ITGAM, JAM3,
LCP2, MUC16, PTPRC, RHOB, SDC2, SNX9
ENG, FAS, HS3ST1, RHOB,
SDC2, SNX9
BGN, FN1,
JAM3, RHOB,
SDC2
CCL5, CCR5, CD2, CD48,
CD86, CSF2RB, FYB, HCK,
LCP2, PTPRC
10 Lymphocyte
migration
2.14E-10 ALOX5, CCL5, CCR5, CD2, CD47, CD48,
CD86, COL1A1, CTSS, DOCK2, EGFR,
ENG, FAS, FN1, FYB, IL15, JAM3, TIMP1,
TNFRSF14, TNFSF13B
ALOX5, CCL5, IL15, TNFSF13B COL1A1, EGFR, ENG, FAS,
TIMP1
CCL5, CCR5, CD2, CD48,
CD86, DOCK2, FYB
IPA nomenclature was used for Functional Annotations. Since analysis for the 10-top-output_mixed_and_4 individual revealed only 5 functional annotations, the results of the 10-top-output_mixed_and_3 individual
are additionally shown. The ranking is based on the corresponding IPA-based p-value of the output_mixed; the molecules mapped to the Functional Annotation are listed
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Table 8 The 10-top-AID/APOBEC signature-linked Upstream Regulators identified by systems biology approach (algorithm I)
Upstream Regulators-10-top-output_mixeda Upstream Regulators output_individualb
APOBEC3G ESR1 ID2 ID3 PTPRC (CD45)
Pos. Upstream
Regulator
P-value Molecules Pos. Molecules Pos. Molecules Pos. Molecules Pos. Molecules Pos. Molecules
1 lipopolysaccharide 2.52E-27 ACTA2, ALOX5, APOBEC3F,
APOBEC3G, APOL6, AR, BGN,
C3AR1, CARD6, CASP1, CCL5,
CCR5, CD48, CD53, CD86,
CDH11, CDKN1A, CIITA,
CLEC7A, COL1A1, COL5A1,
COL6A1, CSF2RB, CTGF,
CYBB, DKK3, FAS, FBN1,
FCER1G, FCGRT, FN1, FYB,
GBP2, GZMA, HCK, ID2,
IFIH1, IGFBP4, IL10RA, IL15,
IRF1, ITGAM, KIAA1551,
LAMB1, LCP2, LST1, NID1,
NID2, PAPSS2, PLEK, PSMB10,
PSMB9, RARRES3, RHOB, SAMSN1,
TFEC, TIMP1, TLR3, TLR8, TNFSF13B,
TRIM22, VCAN, XAF1, ZFP36
2 Interferon alpha 3.48E-19 APOBEC3F, APOBEC3G,
APOL3/APOL4, C3AR1, CASP1,
CCL5, CCR5, CD86, CDKN1A, CIITA,
CSF2RB, EGFR, FAS, GBP2, IFIH1,
IGFBP4, IL10RA, IL15, IRF1, ITGAM,
MNDA, PSMB9, RARRES3, TLR3,
TLR8, TNFSF13B, TRIM22
4 APOBEC3F, APOBEC3G,
APOL3/APOL4, CASP1,
CIITA, IL15, IRF1, TLR3,
TNFSF13B
591 CDKN1A, IGFBP4 146 CSF2RB, TLR8
3 IFNG 7.59E-18 AIF1, APOBEC3G, APOL6, CARD6,
CASP1, CCL5, CCR5, CD2, CD86,
CDKN1A, CIITA, COL1A1, CSF2RB,
CTGF, CTSS, CYBB, FAS, FCER1G,
FN1, GBP2, GMPR, HLA-DOA, ID1,
IFIH1, IGFBP4, IL10RA, IL15, IRF1,
ITGAM, LCP2, LST1, MNDA, PLEK,
PSMB10, PSMB9, RARRES3, RHOB,
SNAI2, TIMP1, TLR3, TLR8, TNFRSF14,
TNFSF13B, TRIM22, ZFP36
1 APOL6, CARD6, CASP1,
CCL5, CIITA, CTSS, GBP2,
IFIH1, IL15, IRF1, ITGAM,
PSMB10, PSMB9, RARRES3,
TLR3, TNFSF13B, TRIM22
7 AIF1, CCL5,
CCR5, CD2,
CD86, CYBB,
FCER1G
4 TGFB1 8.38E-18 ACTA2, ALOX5, BGN, CASP1, CCL5,
CCR5, CD86, CDH11, CDKN1A, CIITA,
COL1A1, COL5A1, COL6A1, COL6A2,
CTGF, CTSS, CYBB, DKK3, DOCK2,
EMILIN1, ENG, FAS, FBN1, FCER1G,
FN1, GMPR, GZMA, HEXB, ID1, ID2,
ID3, IFIH1, IGFBP4, IGFBP7, IL10RA,
IL15, IRF1, ITGAM, ITPR1, PDLIM5,
PLOD1, PMEPA1, PTPRC, RAB31,
161 ALOX5, CCL5, IRF1, ITGAM 3 ACTA2, CDH11,
CDKN1A, COL1A1,
CTGF, ENG, FAS,
HEXB, ID1, RAB31,
RHOB, SNAI2, TIMP1,
ZFP36
3 BGN, CDH11,
COL5A1, FBN1,
FN1, ID1, PMEPA1,
RHOB, SNAI2,
SPOCK1
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Table 8 The 10-top-AID/APOBEC signature-linked Upstream Regulators identified by systems biology approach (algorithm I) (Continued)
RHOB, SNAI2, SPOCK1, TIMP1,
TNFRSF14, TNFSF13B, VCAN,
ZFP36
5 TNF 1.25E-16 ABR, AEBP1, ALOX5, AR, BGN,
CARD16, CARD6, CASP1, CCL5,
CCR5, CD47, CD86, CDH11,
CDKN1A, CIITA, COL1A1, CSF2RB,
CTGF, CTSS, CYBB, EGFR, ENG, ESR1,
FAS, FCER1G, FCGRT, FN1, GBP2,
HEXB, ID1, ID3, IFIH1, IGFBP4, IL10RA,
IL15, IRF1, ITGAM, ITPR1, NID1,
PPAP2A, PSMB10, PSMB9, RARRES3,
SDC2, TIMP1, TLR3, TLR8, TNFSF13B,
ZFP36
7 CASP1, CCL5, CTSS, GBP2,
IL15, IRF1, ITGAM, PSMB10,
PSMB9, RARRES3, TLR3,
TNFSF13B
69 CDH11, CDKN1A,
EGFR, FAS, HEXB,
NID1, PPAP2A,
TIMP1
52 AEBP1, CDH11,
FN1, ITPR1, NID1,
PPAP2A
181 CCL5, CCR5,
CD86, CYBB
6 IL10 1.91E-15 ACTA2, CCL5, CCR5, CD2, CD86,
CDKN1A, CIITA, CLEC7A, COL1A1,
CSF2RB, CTSS, FAS, FCER1G, GZMA,
IGFBP4, IL10RA, IRF1, PSMB9, TIMP1,
TLR3, TLR8, TNFSF13B, VCAN, ZFP36
87 CCL5, CIITA, TLR3 97 ACTA2, CDKN1A,
TIMP1, ZFP36
45 CCL5, CD2,
CD86
7 STAT3 5.98E-15 CASP1, CCL5, CCR5, CD86, CDKN1A,
CIITA, COL5A1, ESR1, FAS, FCER1G,
FN1, GBP2, ID2, IFIH1, IRF1, ITGAM,
PSMB9, SMAD9, TIMP1, TLR3, TRIM14,
TRIM22, VCAN, XAF1, ZFP36
9 CASP1, CIITA, GBP2, IRF1,
ITGAM, PSMB9, TLR3,
XAF1
461 CDKN1A, TIMP1,
ZFP36
106 FN1, SMAD9,
VCAN
8 IL6 2.87E-14 BGN, CASP1, CCL5, CCR5, CD48,
CD53, CD86, CDKN1A, CIITA, CSF2RB,
CTGF, CYBB, EGFR, FAS, FCGRT, FN1,
GBP2, ID1, ID2, IGFBP4, IL15, IRF1,
ITGAM, PSMB10, PSMB9, PTPRC,
RNASE6, TIMP1, TLR3, TLR8
13 CASP1, CIITA, GBP2, IRF1,
ITGAM, PSMB9, TLR3
211 CDKN1A, ID1,
ID2, TIMP1
9 IL13 7.28E-14 C3AR1, CASP1, CCL5, CCR5, CD48,
CD86, CLEC7A, COL1A1, COL6A2,
CTGF, CTSS, CYBB, EGFR, FAS, FGD2,
HOMER2, NID1, SAMSN1, SLA,
SNAI2, TFEC, TIMP1, TNFSF13B
70 CASP1, CCL5, CTSS, FGD2 512 FAS, NID1, TIMP1 1 C3AR1, CCL5,
CCR5, CD48,
CD86, CYBB,
SAMSN1, SLA
10 tretinoin 1.15E-13 C3AR1, CASP1, CCR5, CD53, CD86,
CDKN1A, COL1A1, CTGF, CYBB, DDX60L,
DLC1, EGFR, EYA2, FCER1G, FN1, GZMA,
HS3ST1, ID1, ID2, ID3, IFIH1, IGFBP4,
IGFBP7, IL10RA, IRF1, ITGAM, LAMB1,
MEIS1, MNDA, NID2, PLEK, PSMB9,
RARRES3, SAMD9L, SLA, SMAD9, SOX17,
THSD4, TIMP1, TLR3, TRIM22, XAF1
aThe 10-top-output_mixed results are shown; the ranking is based on the corresponding IPA-based p-value; the molecules associated with the corresponding Upstream Regulator are listed
bPosition of the Upstream Regulator within the output_individual for each target gene, the molecules associated with the Upstream Regulator are indicated. Color code: grey, within the 10-top-output_individual; white,
outside the 10-top-output_individual. Empty cell: the corresponding Upstream Regulator was not significant in output_individual
Svoboda
et
al.BM
C
G
enom
ics
 (2016) 17:643 
Page
20
of
28
Multigene Signature to the Patient-Orientated Clinical
Outcome), can be further applied for any gene-/path-
way-/disease-related signature and any type of tumor
under investigation.
One objective here is the development of proper
multivariable-based models for evaluating patient prog-
nosis on the basis of the patient-specific gene expression
data sets. Although proceedings in whole genome ana-
lysis have triggered the developments of statistical
methods for survival models [68], multivariable Cox re-
gression analysis of multigene-based prognostic models
is still a challenging task based on the following aspects.
Classical statistical regression methods based on max-
imum likelihood have been widely used when the num-
ber of outcome events highly exceeds the number of
variables. In practice, however, we frequently face re-
stricted availability of well-characterized high quality
clinical samples. Thus, in case of a multigene approach,
a relatively large number of profiling-derived variables is
often accompanied by relatively few outcome events
(with respect to OS this is the number of cancer-related
deaths and not the number of patients in the examined
cohort). Given that, herein we established and applied
state-of-the-art algorithms for multivariable modeling
allowing (i) to reduce the risk of getting an overoptimis-
tic or overfitted survival model and, thus, to increase
predictive accuracy; (ii) to be wrapped in a cross-
validation loop in order to estimate the performance of
the model and, importantly, to compare the prognostic
power and accuracy between different models; and (iii)
to be able to rank the contributions of individual vari-
ables to predictions by their importance. We explicitly
applied the leave-one-out strategy of cross-validation in-
stead of dividing the data set in to a training and test
set. We believe that the latter approach is inferior for
several reasons: (i) in a situation of a relatively small
number of events, it would waste a lot of data which
would be needed to obtain more stable estimates; (ii) it
can easily be manipulated by selecting a split that yields
optimal results. To characterize the performances of our
prognostic models, we used PEV, c-index, and p-value,
and these parameters could be used to compare models
within one study but also to make comparisons between
independent studies and laboratories. Thereby, by usage
of those appropriate measures, the truly independent
validation can be performed by an independent group of
researchers and using an independent cohort of patients.
For the examined cohort of patients we herein confirmed
strong prognostic relevance of clinical risk factors and
showed that six clinicopathological variables such as peri-
toneal carcinomatosis, age, histology, FIGO stage, residual
disease, and grading can be assembled into a survival
model which has prognostic power for both OS and PFS.
Importantly, by inclusion of the AID/APOBEC signature-
based variables, the combined model significantly im-
proved the prognostication of OS. Furthermore, several of
the gene profiling-derived variables within the combined
model such as ID3, PTPRC/CD45, AID, APOBEC3G, and
ID2 exceed the prognostic impact of some clinicopatholog-
ical variables to the model. Remarkably, in both models
(ridge and LASSO) ID3 was ranked at the 1st position
overcoming the impact of all six clinical and profiling-
derived variables. Given in addition the strong significance
of ID3 in univariate Cox regression analysis, the data nom-
inate ID3 as prognostic factor for OS. Moreover, since
higher ID3 mRNA levels were associated with poor
survival, further functional studies are needed to validate
whether ID3 might in addition act as a “driver” of patho-
genesis of ovarian cancer. ID molecules (ID1-4) are func-
tional inhibitors/antagonists of the basic helix-loop-helix
transcription factors and thus control the expression of
multiple targets including among others AID [63, 64]. The
critical implications of dysregulated IDs in multiple cancer
hallmarks are highly recognized (reviewed in [69]) includ-
ing contribution to pathomechanisms of ovarian cancer
[38, 70–72]. Small molecule inhibitors of IDs are in devel-
opment and might be considered as novel combinatorial
therapeutic approach for treatment of cancer [73, 74].
For several cancer types (breast, bladder, cervical, head
and neck and lung) an APOBEC mutation pattern was
identified and the APOBEC-mediated mutagenesis was
found to correlate with APOBEC mRNA levels, particu-
larly with APOBEC3B [13, 36]. Furthermore, during our
data mining, the study of Leonard et al. was published
[40] showing elevated expression of APOBEC3B in the
majority of ovarian cancer cell lines examined and in a
subset of high-grade primary ovarian cancer in compari-
son to the normal ovarian or fallopian tube epithelial
cells and non-malignant ovarian tissues, respectively. Al-
though a direct comparison of expression levels between
serous tumor samples and normal ovarian tissues is the
point of debates, which has been as well discussed by
the authors, the accompanied functional studies revealed
a positive association between APOBEC3B expression in
cancer tissues from 16 patients and elevated levels of
transversion mutations, thus, suggesting a contributing
role of APOBEC3B in genomic instability attributed to
ovarian cancer. Against the logical expectations, our data
did not reveal a prognostic relevance of APOBEC3B
mRNA levels in the examined cohort of patients when
assessed by univariate Cox regression analysis. In the
multivariable prognostic models such as AID/APOBEC
or Combined, according to standardized regression
coefficients-based ranking APOBEC3B was assigned to
the positions 7 and 24, respectively, and, thus, showed a
moderate/minimal impact on the prognostic ability of
the models. Our data, however, does not exclude any
additional ways of regulation of APOBEC3B activity in a
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patient-specific manner with respect to disease pathobi-
ology. Besides AID, among APOBEC3 subfamily mem-
bers, APOBEC3G contributed to the prognostic models
(both ridge and LASSO). This might indicate that in
tumor cells during the cancer progression the interplay
between individual APOBEC3 family members plays a
contributing role. Additionally, one should consider the
complex composition of the ovarian cancer tissues used
for the gene expression profiling, which besides the
tumor cells includes the tumor stroma with significant
component attributed to infiltrated immune cell popula-
tions; thus, the AID/APOBEC mRNA expression values
likely reflex the sum from all positive cells. Indeed, on
the one side, the herein performed expression analysis of
the signature genes using a wide range of ovarian cancer
cell lines showed that those innate/adaptive immunity-
related genes might as well be expressed in ovarian
tumor cells per se; our data are generally in line with the
profiling results reported recently [40]. On the other
side, the correlation analysis of multigene-derived data
sets across ovarian cancer tissues revealed strong posi-
tive association between PTPRC/CD45, the classical im-
mune cell marker, and APOBEC3 subfamily members
such as A3C, A3D, A3H, and the prognostically relevant
A3G as well as AID. Furthermore, although weaker, a
positive association was observed with PAX5, the B-cell
transcription factor. These data suggest that, besides ex-
pression by tumor cells, certain contributions from im-
mune cells, including B lymphocytes, to the total mRNA
expression levels of individual APOBECs indeed might
take place which thereby impacts the prognostic power
of the model. Of note, no significant correlation was
found between PTPRC/CD45 and APOBEC3B, thus,
likely excluding the major impact of the CD45-positive
immune cells to this variable.
It is important to emphasize that within the prognostic
model APOBEC3G behaves as a protective factor with
potential anti-tumor action since higher APOBEC3G
mRNA expression levels were associated with better
clinical outcome in respect of OS. Previous cell-based
studies showed that APOBEC3G does not fall into the
subclass of APOBECs (which among others includes
APOBEC3B) grouped based on mutational specificity for
TC motifs [75] suggesting somewhat different APO-
BEC3G-mediated biological consequences. Considering
the APOBEC3 functions in virus, naked foreign DNA or
retrotransposon restriction, a potential association be-
tween the APOBEC expression, the APOBEC-mediated
cancer-related mutagenesis and the viral infection/viral
carcinogenesis is appealing and was discussed recently,
when two cancer types, cervical and head and neck can-
cer, which are highly associated with human papilloma-
virus, HPV, were found among those six types with
strong enrichment of APOBEC-mediated mutagenic
patterns [36, 76]; HPV in turn is one of the known
APOBEC3-targeted viruses [77, 78] (besides well-studied
HIV-1, the list includes HTLV, HCV, HBV, HPV, HSV-1,
and EBV). Such association in ovarian cancer is cur-
rently not known.
Data-driven disease-relevant pathways
The third analytical module applied herein allowed us to
extend the signature- and modeling-based knowledge
and dissect potential mechanisms/pathways/factors con-
tributing to disease pathogenesis and patient survival.
The reconstructed network was created and visualized
using the IPA software on the basis of the target mole-
cules defined by prognostic modeling and the molecules
from co-expressed genes derived from the 10-top Ca-
nonical Pathways and Upstream Regulators (Fig. 4). This
integration and visualization of both experimental and
in silico microarray-based data illustrate the existence of
mutual interconnections between four target genes such
as PTPRC/CD45, ID3, APOBEC3G, ID2 and point to
more separate biological function(s) of the node around
ESR1 in advanced stage serous ovarian cancer.
Generally, the 10-top Canonical Pathways contain
molecules which are characteristic for tissue remodel-
ing/fibrotic pathway, altered immune response including
antigen presentation mechanisms, and communication
between various immune cell populations involved in in-
nate and adaptive immune responses. It gives a link to
autoimmune disorders with inflammatory background as
rheumatoid arthritis and to transplant rejection by the
recipient’s immune system and, unsuspectedly, does not
highlight the cancer-related processes. Notably, among
the top Canonical Pathways, the first top-ranked was
Hepatic Fibrosis/Hepatic Stellate Cell Activation based
on such molecules as COL1A1, IGFBP4, CCR5, FN1,
CTGF, TIMP1, ACTA2, IL10RA, CCL5, FAS, EGFR. The
significant association between fibrosis and the clinical
outcome of ovarian cancer patients was observed re-
cently by others, although it was identified by applying
completely different approaches such as miRNA screen-
ing or histological examinations, respectively [79, 80].
Surprisingly, the same pathway was identified as one of
the most relevant canonical pathways in granulosa cells
from bovine ovarian follicles during atresia, which repre-
sents one of the physiological processes in healthy ovar-
ies [81]. Thus, aberrant modulation of the pathway’s
underlying molecules might turn the physiological pro-
cesses to the direction of malignant transformation.
Multiple Canonical Pathways within the identified 10-
top are linked to the antigen processing and presentation
machinery and antigen recognition by lymphocytes
(Fig. 4 and Table 4, pos. 2, 3, 6, 9, and 10); HLA class II
transcripts are among the molecules underlying these
pathways. In this respect it is interesting to note that the
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recent study by Yoshihara et al. [82] identified the anti-
gen presentation pathway to be significantly modulated
(as estimated by downregulation of HLA class I mole-
cules) in a high risk group compared with a low risk
group of patients with high-grade serous ovarian cancer.
The top Functional Annotations & Diseases and Up-
stream Regulators of the AID/APOBEC-associated net-
work reconstruction further indicate the particular
significance of immunity, aberrant immunity/auto-
immunity and inflammation. Rather unexpectedly, the
categories such as rheumatic diseases, arthritis, rheuma-
toid arthritis were top-ranked together with more broad
functions such as proliferation of cells, binding of cells,
cell movement including movement of various immune
cell subsets (lymphocytes, myeloid cells, phagocytes),
and quantity of leukocytes. The identified association
with rheumatoid arthritis – the progressive inflamma-
tory autoimmune disorder – further points out to the
importance/relevance of inflammation and suggests an
autoimmune phenomenon as potential novel aspect in
pathophysiology of ovarian cancer. It is important to
note that the cytokines most directly implicated in the
pathophysiology of rheumatoid arthritis are proinflam-
matory TNFalpha and IL-6 [83]; herein these molecules
are ranked within the 10-top most significantly over-
represented regulators. Intriguingly, both TNFalpha and
Fig. 4 Representation of the top Canonical Pathways, Functional Annotations and Upstream Regulators detected upon analysis of target genes
and their co-regulated genes. A reconstructed gene network was created using the Ingenuity Pathway Analysis Software (IPA) on the basis of the
target molecules, the molecules from the 10-top Canonical Pathways (see Table 4, Molecules) and the 10-top Upstream Regulators (see Table 8).
Solid lines in grey display the IPA-identified direct interactions between the molecules; dashed lines display indirect interactions. The multigene
approach-based correlation analysis was used to find additional biological associations between the target genes. Statistically significant study-
based associations (SPSS program, Additional file 1: Table S5) are displayed by dashed lines; red for correlation coefficient ≥ 0.6, p < 0.001; blue for
correlation coefficient < 0.6, p < 0.001. The 10-top Canonical Pathways are listed according to the IPA-based ranking (from left to right). For a
complete overview, also the most significant Functional Annotations & Diseases are shown (see Tables 5, 6 and 7)
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in particular IL-6 have been previously shown to pro-
mote epithelial ovarian tumorigenesis and cancer pro-
gression (reviewed in [84]). Numerous preclinical and
translational studies emphasize the rational of targeting
the IL-6/IL-6-signaling pathways in cancer, considering
among others ovarian carcinoma, either as single treat-
ment or in combination with other chemotherapeutic
drugs [85, 86]; reviewed in [87]. The present study sup-
ports this notion. Furthermore, it proposes for consider-
ation/reconsideration the assessment of IL-6 and other
markers of arthritis including systemic autoantibodies
and, as proposed previously, C-reactive protein [88] for
monitoring the disease and therapy response in ovarian
cancer. Noteworthy, data of recent epidemiological stud-
ies suggest an increased risk of developing ovarian can-
cer for patients with rheumatoid arthritis at advanced
stage of disease; for entire, unstratified patient group the
association was reported to be inverse [89].
Besides that, the data unexpectedly suggest that the
therapeutic regiments considered for treatment of HIV
by mechanism(s) of enhancing the APOBEC3G expres-
sion/activity might be added for consideration for the
stratified group of high risk patients with serous ovarian
cancer. Among those are IFNalpha and novel IFN-
related mimetics preserving beneficial antiviral roles
while minimizing negative effects [90]. It is important to
emphasize that based on different argumentations and
accenting the immunomodulatory and antiproliferative
activities of IFNs family, the attempts have been already
made to establish IFN as a standard in the treatment of
ovarian cancer [91, 92]. However, the results were not
monosemantic among the various clinical trials. This
stresses the complexity of the disease and strongly indi-
cates the necessity to stratify the patient population
prior to drug application. Small molecules as agonists or
antagonists [93, 94], which are able to modulate specific-
ally the APOBEC3G and APOBEC3B levels and activ-
ities, respectively, can be as well considered as starting
points for further development of combinatorial drug
applications in ovarian cancer. Still, there is much to
clarify regarding the expression patterns of APOBEC3G
(as well as APOBEC3B) on the protein transcript levels
in respect of the immune contexture and tumor anat-
omy applying the methodology of computerized assess-
ment of large-scale ovarian cancer tissue sections
(examples in [95, 96]).
We herein used a well-characterized patient cohort at
advanced stage of ovarian cancer. This cohort reflects
the current clinical situation in the medical care of ovar-
ian cancer patients as most cases of ovarian cancer are
diagnosed at advanced stages of disease due to incon-
spicuous symptoms and lack of reliable biomarkers [97].
Based on that, the data-driven conclusion likely suggests
the contribution of AID/APOBEC-triggered mechanisms
to the disease progression. However, their cancer-
causing role cannot be as well excluded.
Conclusions
The herein defined analysis algorithm, MuSiCO, allows
to establish a link between AID/APOBEC-associated
gene expression profiles and patient survival, and to fur-
ther delineate novel disease-associated pathways/net-
works. Based on the results of complex multivariable
modeling, we propose a novel strategy for risk assess-
ment of patients with primary ovarian cancer by integra-
tion of AID/APOBEC signature-based data sets and
clinical risk factors into a combined survival model. We
evaluated the performance of various prognostic models
based on PEV, c-index and p-value. We propose to use
these parameters to compare models not only within
one study but also to make comparisons between inde-
pendent studies and laboratories. Furthermore, we re-
constructed a gene regulatory network on the basis of
target molecules defined by prognostic modeling and the
molecules from co-expressed genes derived from curated
transcriptome-based expression data from the serous
ovarian cancer-based studies. These findings link the ex-
pression pattern of AID/APOBEC-associated genes with
remodeling/fibrotic pathways, altered immune response,
and autoimmune disorders with inflammatory back-
ground (Fig. 4), and propose for a consideration of po-
tential novel biomarkers and/or targets and therapeutic
regiments, although with a strong indication for neces-
sity to stratify the patient population prior to drug appli-
cation. Among them are APOBEC3G, AID, ID3, IL-6,
IFNalpha and novel IFN-related mimetics. This study
additionally suggest to consolidate the acquired know-
ledge and research efforts in the fields of virology and
cancer research around AID/APOBECs expression and
functionality as well as drug targeting and drugs in
development.
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